Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy

C. C. F. M. J. Baaten; F. C. J. I. Moenen; Y. M. C. Henskens; F. Swieringa; R. Wetzels; R. van Oerle; H. ten Cate; E. A. M. Beckers; J. W. M. Heemskerk; P. E. J. van der Meijden

doi:10.1016/s0049-3848(16)30125-6

Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy

C. C. F. M. J. Baaten, F. C. J. I. Moenen, Y. M. C. Henskens, F. Swieringa, R. Wetzels, R. van Oerle, H. ten Cate, E. A. M. Beckers, J. W. M. Heemskerk, P. E. J. van der Meijden

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Web of Science)

Abstract

Introduction severe thrombocytopenia (= 50 × 109 platelets/l) is often the consequence of hematological malignancies and intensive chemotherapy. The risk of clinically significant bleeding is increased in these patients, despite the use of prophylactic platelet transfusions. The fact that there is no clear correlation between the platelet count and the risk of hemorrhage, suggests that there are other contributing factors. The contribution of impairments in platelet and coagulant function remains poorly understood.

Original language	English
Pages (from-to)	S171-S171
Journal	Thrombosis Research
Volume	140S1
DOIs	https://doi.org/10.1016/s0049-3848(16)30125-6
Publication status	Published - Apr 2016

Access to Document

10.1016/s0049-3848(16)30125-6

Cite this

Baaten, C. C. F. M. J., Moenen, F. C. J. I., Henskens, Y. M. C., Swieringa, F., Wetzels, R., van Oerle, R., ten Cate, H., Beckers, E. A. M., Heemskerk, J. W. M., & van der Meijden, P. E. J. (2016). Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy. Thrombosis Research, 140S1, S171-S171. https://doi.org/10.1016/s0049-3848(16)30125-6

@article{f41b2e4c0a934e16a6ba7d019e0558ae,

title = "Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy",

abstract = "Introduction severe thrombocytopenia (= 50 × 109 platelets/l) is often the consequence of hematological malignancies and intensive chemotherapy. The risk of clinically significant bleeding is increased in these patients, despite the use of prophylactic platelet transfusions. The fact that there is no clear correlation between the platelet count and the risk of hemorrhage, suggests that there are other contributing factors. The contribution of impairments in platelet and coagulant function remains poorly understood.",

author = "Baaten, {C. C. F. M. J.} and Moenen, {F. C. J. I.} and Henskens, {Y. M. C.} and F. Swieringa and R. Wetzels and {van Oerle}, R. and {ten Cate}, H. and Beckers, {E. A. M.} and Heemskerk, {J. W. M.} and {van der Meijden}, {P. E. J.}",

year = "2016",

month = apr,

doi = "10.1016/s0049-3848(16)30125-6",

language = "English",

volume = "140S1",

pages = "S171--S171",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Science",

}

TY - JOUR

T1 - Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy

AU - Baaten, C. C. F. M. J.

AU - Moenen, F. C. J. I.

AU - Henskens, Y. M. C.

AU - Swieringa, F.

AU - Wetzels, R.

AU - van Oerle, R.

AU - ten Cate, H.

AU - Beckers, E. A. M.

AU - Heemskerk, J. W. M.

AU - van der Meijden, P. E. J.

PY - 2016/4

Y1 - 2016/4

N2 - Introduction severe thrombocytopenia (= 50 × 109 platelets/l) is often the consequence of hematological malignancies and intensive chemotherapy. The risk of clinically significant bleeding is increased in these patients, despite the use of prophylactic platelet transfusions. The fact that there is no clear correlation between the platelet count and the risk of hemorrhage, suggests that there are other contributing factors. The contribution of impairments in platelet and coagulant function remains poorly understood.

AB - Introduction severe thrombocytopenia (= 50 × 109 platelets/l) is often the consequence of hematological malignancies and intensive chemotherapy. The risk of clinically significant bleeding is increased in these patients, despite the use of prophylactic platelet transfusions. The fact that there is no clear correlation between the platelet count and the risk of hemorrhage, suggests that there are other contributing factors. The contribution of impairments in platelet and coagulant function remains poorly understood.

U2 - 10.1016/s0049-3848(16)30125-6

DO - 10.1016/s0049-3848(16)30125-6

M3 - Article

VL - 140S1

SP - S171-S171

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -